文献速递中毒与环境急症呼吸衰竭与机械通气

肌注纳洛酮1600 μg联合滴定静注纳洛酮100 μg治疗阿片类药物中毒的有效性:一项随机对照试验

Effectiveness of intramuscular naloxone 1,600 μg in addition to titrated intravenous naloxone 100 μg for opioid poisoning: a randomised controlled trial.
PubMed 文献 · Clin Toxicol (Phila) · 2024-09-05
一句话结论在滴定静注纳洛酮基础上加用肌注纳洛酮1600 μg,可减少4小时内呼吸抑制复发(41% vs 72%,P<0.001),且不增加戒断症状。

这项双盲随机安慰剂对照试验纳入疑似阿片类药物中毒伴呼吸抑制(呼吸频率<10次/分或血氧饱和度<93%)的患者,比较肌注纳洛酮1600 μg与生理盐水安慰剂,所有患者均接受滴定静注纳洛酮100 μg并按阿片类药物中毒护理路径管理。主要终点为4小时内呼吸抑制复发,肌注组28/69(41%)显著低于安慰剂组48/67(72%)(差值31%,95%CI 13-46%,P<0.001)。肌注组接受纳洛酮输注比例更低(5/69,7% vs 25/67,37%,P<0.001),纳洛酮给药次数更少(中位数2次 vs 5次,P=0.001)。10分钟呼吸抑制逆转率两组相似(74% vs 70%,P=0.703),阿片戒断症状发生率无显著差异(51% vs 42%,P=0.308)。

要点

  • 疑似阿片中毒伴呼吸抑制(呼吸频率<10次/分或血氧饱和度<93%)患者,在滴定静注纳洛酮100 μg基础上加用肌注纳洛酮1600 μg,4小时内呼吸抑制复发率41%(28/69)显著低于安慰剂组72%(48/67)(P<0.001)。
  • 加用肌注纳洛酮1600 μg使需要纳洛酮输注的患者比例从37%(25/67)降至7%(5/69)(P<0.001),纳洛酮给药次数中位数从5次(IQR 2-8)降至2次(IQR 1-5)(P=0.001)。
  • 10分钟时呼吸抑制逆转率肌注组74%(51/69)与安慰剂组70%(47/67)相似(P=0.703)。
  • 阿片戒断症状(任何症状)发生率肌注组51%(35/69)与安慰剂组42%(28/67)无显著差异(差值9%,95%CI -8至27%,P=0.308)。

适用人群与场景

  • 疑似阿片类药物中毒且伴呼吸抑制的患者,呼吸抑制定义为呼吸频率<10次/分或血氧饱和度<93%。

诊断标准与关键阈值

  • 呼吸抑制定义:呼吸频率<10次/分或血氧饱和度<93%。

处置流程与药物剂量

  • 所有患者接受滴定静注纳洛酮100 μg,并按阿片类药物中毒护理路径管理。
  • 随机给予肌注纳洛酮1600 μg或生理盐水安慰剂。

研究设计与关键结果

  • 双盲随机安慰剂对照试验:疑似阿片中毒伴呼吸抑制患者随机接受肌注纳洛酮1600 μg(n=69)或安慰剂(n=67),均接受滴定静注纳洛酮100 μg。
  • 主要终点4小时内呼吸抑制复发:肌注组28/69(41%)vs 安慰剂组48/67(72%),差值31%(95%CI 13-46%),P<0.001。
  • 接受纳洛酮输注比例:肌注组5/69(7%)vs 安慰剂组25/67(37%),差值30%(95%CI 15-55%),P<0.001。
  • 纳洛酮给药次数:肌注组中位数2次(IQR 1-5)vs 安慰剂组中位数5次(IQR 2-8),P=0.001。
  • 10分钟呼吸抑制逆转率:肌注组51/69(74%)vs 安慰剂组47/67(70%),P=0.703。
  • 阿片戒断症状(任何症状)发生率:肌注组35/69(51%)vs 安慰剂组28/67(42%),差值9%(95%CI -8至27%),P=0.308。

证据类型、等级与局限

  • 证据类型:双盲随机安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于疑似阿片中毒伴呼吸抑制(呼吸频率<10次/分或血氧饱和度<93%)的患者,在滴定静注纳洛酮100 μg基础上加用肌注纳洛酮1600 μg,可延长呼吸抑制的有效逆转,减少纳洛酮给药次数和输注需求。
  • 加用肌注纳洛酮1600 μg未显著增加阿片戒断症状的发生。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Naloxone is an effective antidote, but its short half-life means repeated doses, and infusions are often required. We investigated the effectiveness of adding intramuscular naloxone to titrated intravenous naloxone in opioid overdose in preventing recurrence of respiratory depression.

METHODS: This double-blinded randomised placebo-controlled trial was conducted in patients with suspected opioid poisoning and respiratory depression (respiratory rate <10 breaths/min or oxygen saturation <93%). Patients were randomised to receive either intramuscular naloxone 1,600 µg or saline placebo. All patients received titrated intravenous naloxone 100 µg and were managed on an opioid poisoning care pathway. The primary outcome was recurrence of respiratory depression within 4 h. Secondary outcomes were the proportion receiving naloxone infusions, number of naloxone boluses administered, reversal of respiratory depression at 10 min, and precipitation of opioid withdrawal (any symptom).

RESULTS: Recurrence of respiratory depression within 4 h was less common in 28/69 (41%) patients receiving intramuscular naloxone versus 48/67 (72%) patients receiving placebo (difference 31%, 95% CI: 13-46%; P < 0.001). Fewer naloxone infusions (5/69; 7% versus 25/67; 37%, difference 30%, 95% CI: 15 to 55%; P < 0.001) and fewer naloxone doses were administered (median 2, IQR: 1 to 5, versus median 5, IQR: 2 to 8; P = 0.001) in the intramuscular group. Reversal of respiratory depression at 10 min was similar between groups (51/69; 74% intramuscular naloxone versus 47/67; 70% placebo; P = 0.703). Opioid withdrawal occurred in 35/69 (51%) given intramuscular naloxone compared to 28/67 (42%) in the placebo group (difference 9%; 95% CI: -8 to 27%; P = 0.308).

DISCUSSION: The favourable pharmacokinetics of intramuscular naloxone, particularly its longer duration of activity, likely explains the improved effectiveness with lower recurrence of respiratory depression.

CONCLUSION: The addition of intramuscular naloxone 1,600 µg to titrated intravenous naloxone prolonged effective reversal of respiratory depression, with fewer naloxone doses and infusions given, and no significant difference in patients developing withdrawal.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Isoardi KZ, Harris K, Currey E, et al. Effectiveness of intramuscular naloxone 1,600 μg in addition to titrated intravenous naloxone 100 μg for opioid poisoning: a randomised controlled trial. Clin Toxicol (Phila). 2024. PMID: 39235169. doi:10.1080/15563650.2024.2396447

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。